<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04689100</url>
  </required_header>
  <id_info>
    <org_study_id>JMT101-ECL</org_study_id>
    <nct_id>NCT04689100</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of JMT101 in Patients With Advanced Solid Tumor</brief_title>
  <official_title>A Phase I, Open Label, Multi-center Study to Assess the Efficacy and Safety of JMT101 in Patients With Advanced Solid Tumor.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai JMT-Bio Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CSPC ZhongQi Pharmaceutical Technology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai JMT-Bio Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a Phase I, open label, multi-center study of to evaluate the safety and&#xD;
      efficacy of JMT101 in patients with advanced solid tumor.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of the trial is to evaluate the safety and efficacy of JMT101 in patients with&#xD;
      advanced solid tumor.&#xD;
&#xD;
      This study consists of two parts (Stage I and Stage II). Stage I was a dose escalation study,&#xD;
      and Stage II was a dose expansion study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 11, 2017</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events (defined by the Common Terminology Criteria for Adverse Events version 4.03 (CTCAE V4.03)).</measure>
    <time_frame>From enrollment until 30 days after the last dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects Experiencing DLTs (Dose Limiting Toxicity).</measure>
    <time_frame>Time from the first dose of study drug up to 4 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD)</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>From first dose to disease progression or end of study, an average of 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR).</measure>
    <time_frame>From first dose to disease progression or end of study, an average of 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS).</measure>
    <time_frame>From first dose to disease progression or end of study, an average of 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS).</measure>
    <time_frame>From first dose to death or end of study, an average of 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration curve from time 0 to the concentration at last time point (AUC0-last) of JMT101.</measure>
    <time_frame>From enrollment until 30 days after the last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum measured plasma concentration (Cmax) of JMT101.</measure>
    <time_frame>From enrollment until 30 days after the last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum plasma concentration (Tmax) of JMT101.</measure>
    <time_frame>From enrollment until 30 days after the last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life (T1/2) of JMT101.</measure>
    <time_frame>From enrollment until 30 days after the last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity profile of JMT101.</measure>
    <time_frame>From enrollment until 30 days after the last dose</time_frame>
    <description>Blood samples will be collected from subjects post treatment for assessment to detect the presence of anti-drug antibodies(ADA) and neutralizing antibodies by electrochemical luminescence(ECL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Potential biomarkers detected in plasma or tumor issue DNA.</measure>
    <time_frame>From enrollment up to disease progression, an average of 1 year</time_frame>
    <description>The content of RAS(reticular activating system), EGFR(epidermal growth factor receptor), BRAF(B-Raf proto-oncogene) gene will be detected.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">259</enrollment>
  <condition>Advanced Solid Tumor</condition>
  <arm_group>
    <arm_group_label>Dose Escalation Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Monotherapy: Six dose levels of JMT101 will be tested according to an accelerated titration method followed by a conventional 3 + 3 study design.&#xD;
Combined with chemotherapy: Three dose levels of JMT101 will be tested by a conventional 3 + 3 study design.&#xD;
The dose-limiting toxicity (DLT) will be assessed from the first administration to the end of the first cycle (28 days).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once the effective dose has been determined, an expansion cohort will be opened to evaluate the efficacy and safety of the selected dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JMT101</intervention_name>
    <description>Monotherapy: Accelerated titration method, IV infusion QW; Conventional 3 + 3 study design, IV infusion Q2W. (28-day cycles) Combined with chemotherapy: Conventional 3 + 3 study design, IV infusion Q2W. (28-day cycles)</description>
    <arm_group_label>Dose Escalation Cohort</arm_group_label>
    <other_name>FOLFIRI(Irinotecan, Leucovorin Calcium, and Fluorouracil); mFOLFOX6((Oxaliplatin, Leucovorin Calcium, and Fluorouracil);</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JMT101</intervention_name>
    <description>IV infusion Q2W (28-day cycles)</description>
    <arm_group_label>Dose Expansion Cohort</arm_group_label>
    <other_name>FOLFIRI; mFOLFOX6; Irinotecan;</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Monotherapy: Pathologically or cytologically confirmed, advanced solid tumor,&#xD;
             harboring RAS wild type; Combined with chemotherapy: Pathologically or cytologically&#xD;
             confirmed, locally advanced /metastatic colorectal cancer, harboring RAS and BRAF&#xD;
             V600E wild type.&#xD;
&#xD;
          -  At least 1 measurable lesion according to RECIST 1.1;&#xD;
&#xD;
          -  ECOG score 0 or 1;&#xD;
&#xD;
          -  Stable for more than 14 days of brain metastasis or spinal cord compression.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Receipt of any EGFR inhibitors within 5 months prior to the first dose of study&#xD;
             treatment.&#xD;
&#xD;
          -  The second primary malignant tumor was diagnosed within 5 years prior to the first&#xD;
             dose of study treatment.&#xD;
&#xD;
          -  Known hypersensitivity to any ingredient of JMT101 or their excipients;&#xD;
&#xD;
          -  Major surgery within prior 4 weeks of first treatment.&#xD;
&#xD;
          -  Receiving an investigational product in another clinical study within 4 weeks;&#xD;
&#xD;
          -  History of serious systemic diseases;&#xD;
&#xD;
          -  Pregnancy or lactating wo&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiugao Yang</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Medicine, CSPC Clinical Development Division</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiugao Yang</last_name>
    <phone>8021-60677906</phone>
    <email>yangxiugao@mail.ecspc.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rong Hu</last_name>
    <phone>8021-60673935</phone>
    <email>hurong@mail.ecspc.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Beijing Luhe Hospital. Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dong Yan</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peking University Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lin Shen</last_name>
      <phone>8010-88196561</phone>
      <email>linshenpku@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The first affiliated hospital of bengbu medical college</name>
      <address>
        <city>Bengbu</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jun Qian</last_name>
    </contact>
    <investigator>
      <last_name>Jun Qian</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Huan Zhou</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First People's Hospital of Changzhou</name>
      <address>
        <city>Changzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wenwei Hu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chongqing University Cancer Hospital</name>
      <address>
        <city>Chongqing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Weiqi Nian</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Sixth Affiliated Hospital, Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yanhong Deng</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhongshan Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tianshu Liu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Soochow University</name>
      <address>
        <city>Suzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Weichang Chen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Henan Cancer Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jufeng Wang</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 23, 2020</study_first_submitted>
  <study_first_submitted_qc>December 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 30, 2020</study_first_posted>
  <last_update_submitted>December 25, 2020</last_update_submitted>
  <last_update_submitted_qc>December 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Calcium</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

